Physiologically based pharmacokinetic modeling of ritonavir-oxycodone drug interactions and its implication for dosing strategy
This study was aimed to simulate DDI between ritonavir and oxycodone, a widely used opioid, and to formulate dosing protocols for oxycodone by using physiologically based pharmacokinetic (PBPK) modeling. We developed a ritonavir PBPK model incorporating induction and competitive and time-dependent inhibition of CYP3A4 and competitive inhibition of CYP2D6. The ritonavir model was evaluated with observed clinical pharmacokinetic data and validated for its CYP3A4 inhibition potency. We then used the model to simulate drug interactions between oxycodone and ritonavir under various dosing scenarios. The developed model captured...
Source: European Journal of Pharmaceutical Sciences - January 10, 2024 Category: Drugs & Pharmacology Authors: Liang Zheng Wei Zhang Klaus T Olkkola Andr é Dallmann Liang Ni Yingjie Zhao Ling Wang Qian Zhang Wei Hu Source Type: research
Blocking IL-17A prevents oxycodone-ineduced depression-like effects and elevation of IL-6 levels in the ventral tegmental area and reduces oxycodone-derived physical dependence in rats
Brain Behav Immun. 2024 Jan 8;117:100-111. doi: 10.1016/j.bbi.2024.01.001. Online ahead of print.ABSTRACTOxycodone is the most prescribed opioid for pain management and has been available in clinics for almost a century, but effects of chronic oxycodone have been studied less than morphine in preclinical and clinical studies. Newly developed depression has been coupled with chronic oxycodone use in a few clinical studies, but no preclinical studies have investigated the pathogenesis of oxycodone-induced depression. Gut microbiome changes following oxycodone use is an understudied area, and interleukin-17A (IL-17A) is linke...
Source: Brain, Behavior, and Immunity - January 10, 2024 Category: Neurology Authors: Saadet Inan Joseph J Meissler Shingo Bessho Sonita Wiah Cagla Tukel Toby K Eisenstein Scott M Rawls Source Type: research
Simultaneous determination of 14 analgesics in postoperative analgesic solution by HPLC –DAD and LC–MS/MS
A green, efficient, sensitive and accurate detection method by HPLC –DAD and LC–MS/MS was developed and validated for the quantification of morphine, hydromorphone, oxycodone, ketamine tramadol, dezocine, ropiv... (Source: Chemistry Central Journal)
Source: Chemistry Central Journal - January 10, 2024 Category: Chemistry Authors: Manman Yao, Baoxia Fang, Jinguo Yang, Sicen Wang and Fuchao Chen Tags: Research Source Type: research
Comparing the effects of decreasing prescription opioid shipments and the release of an abuse deterrent OxyContin formulation on opioid overdose fatalities in WV: an interrupted time series study
The 2010 release of an abuse deterrent formulation (ADF) of OxyContin, a brand name prescription opioid, has been cited as a major driver for the reduction in prescription drug misuse and the associated increa... (Source: Substance Abuse Treatment, Prevention, and Policy)
Source: Substance Abuse Treatment, Prevention, and Policy - January 4, 2024 Category: Addiction Authors: Eric W. Lundstrom, Zheng Dai, Caroline P. Groth, Brian Hendricks, Erin L. Winstanley, Marie Abate and Gordon S. Smith Tags: Research Source Type: research
Exploring the Impact of CYP2D6 and UGT2B7 Gene-Drug Interactions, and CYP-mediated DDI on Oxycodone and Oxymorphone Pharmacokinetics using Physiologically-Based Pharmacokinetic Modelling and Simulation
Eur J Pharm Sci. 2024 Jan 1:106689. doi: 10.1016/j.ejps.2023.106689. Online ahead of print.ABSTRACTOxycodone is one of the most commonly used opioids to treat moderate to severe pain. It is metabolized mainly by CYP3A4 and CYP2D6, while only a small fraction of the dose is excreted unchanged into the urine. Oxymorphone, the metabolite primarily formed by CYP2D6, has a 40- to 60-fold higher mu-opioid receptor affinity than the parent compound. While CYP2D6-mediated gene-drug-interactions (GDIs) and drug-drug interactions (DDIs) are well-studied, they only account for a portion of the variability in oxycodone and oxymorphone...
Source: European Journal of Pharmaceutical Sciences - January 3, 2024 Category: Drugs & Pharmacology Authors: Marian Klose Rodrigo Cristofoletti Carolina de Miranda Silva Naveen Mangal Jacques Turgeon Veronique Michaud Lawrence J Lesko Stephan Schmidt Source Type: research
A bacteriophage virus-like particle vaccine against oxycodone elicits high-titer and long-lasting antibodies that sequester drug in the blood
In this study, we investigated Qβ bacteriophage virus-like particles (VLPs) as a vaccine platform for immunogenic display of oxycodone. A derivative of oxycodone was conjugated to pre-formed Qβ VLPs using a sulfhydryl-amine reactive heterobifunctional crosslinker with high loading of oxycodone. In mice, intramuscular immunization with Qβ-oxycodone elicited high-titer, high-avidity and long-lasting antibody responses. Qβ-oxycodone was also immunogenic after storage at ambient room temperature for over two weeks, demonstrating that the vaccine is highly thermostable. In mice, immunization with Qβ-oxycodone elicited anti...
Source: Vaccine - December 30, 2023 Category: Allergy & Immunology Authors: Isabella G Romano Susan B Core Naomi R Lee Curtis Mowry Koen K A Van Rompay Yumei Huang Bryce Chackerian Kathryn M Frietze Source Type: research
Barriers and Best Practices on the Management of Opioid Use Disorder
This article provides an overview of the pharmacology of heroin and non-prescription fentanyl (NPF) and its synthetic analogues, and summarizes the literature related to the management of opioid use disorder, overdose, and withdrawal. This is followed by a description of barriers to treatment and best practices for management with a discussion on recent updates and their potential impact on this patient population. This is followed by a description of barriers to treatment and best practices for management with a discussion on recent updates and their potential impact on this patient population.PMID:38100521 | DOI:10.1080/...
Source: Journal of Pain and Palliative Care Pharmacotherapy - December 15, 2023 Category: Palliative Care Authors: Michelle Krichbaum Daniela Fernandez Devada Singh-Franco Source Type: research
Correction to "Oxycodone: A Current Perspective on Its Pharmacology, Abuse, and Pharmacotherapeutic Developments"
Pharmacol Rev. 2023 Dec 15;76(1):195. doi: 10.1124/pharmrev.121.000506err.NO ABSTRACTPMID:38101935 | DOI:10.1124/pharmrev.121.000506err (Source: Pharmacological Reviews)
Source: Pharmacological Reviews - December 15, 2023 Category: Drugs & Pharmacology Source Type: research
Barriers and Best Practices on the Management of Opioid Use Disorder
This article provides an overview of the pharmacology of heroin and non-prescription fentanyl (NPF) and its synthetic analogues, and summarizes the literature related to the management of opioid use disorder, overdose, and withdrawal. This is followed by a description of barriers to treatment and best practices for management with a discussion on recent updates and their potential impact on this patient population. This is followed by a description of barriers to treatment and best practices for management with a discussion on recent updates and their potential impact on this patient population.PMID:38100521 | DOI:10.1080/...
Source: Journal of Pain and Palliative Care Pharmacotherapy - December 15, 2023 Category: Palliative Care Authors: Michelle Krichbaum Daniela Fernandez Devada Singh-Franco Source Type: research
Correction to "Oxycodone: A Current Perspective on Its Pharmacology, Abuse, and Pharmacotherapeutic Developments"
Pharmacol Rev. 2023 Dec 15;76(1):195. doi: 10.1124/pharmrev.121.000506err.NO ABSTRACTPMID:38101935 | DOI:10.1124/pharmrev.121.000506err (Source: Pharmacological Reviews)
Source: Pharmacological Reviews - December 15, 2023 Category: Drugs & Pharmacology Source Type: research
Contextualising opioid-related risk factors before an initial opioid prescription
When asked about the similarities between the region of Valencia, Spain and the State of Oregon in the USA, an artificial-intelligence (AI)-driven chatbot poetically listed several common features, such as natural beauty, strong focus on agricultural industries including wine production, extensive outdoor activities and a shared commitment to sustainable practices. But are there similarities in healthcare delivery, considering vastly different systems and significant practice variability, particularly regarding the management of pain and the role of opioid analgesics? Here, the differences emerge. Oxycodone and hydrocodone...
Source: BMJ Quality and Safety - December 14, 2023 Category: General Medicine Authors: Weiner, S. G., Hoppe, J. A. Tags: Editorials Source Type: research
Oxycodone, an opioid like the others?
The over-prescription of opioid analgesics is a growing problem in the field of addiction, which has reached epidemic-like proportions in North America. Over the past decade, oxycodone has gained attention as the leading opioid responsible for the North America opioid crisis. Oxycodone is the most incriminated drug in the early years of the epidemic of opioid use disorder in USA (roughly 1999–2016). The number of preclinical articles on oxycodone is rapidly increasing. Several publications have already compared oxycodone with other opioids, focusing mainly on their analgesic properties. The aim of this review is to focus...
Source: Frontiers in Psychiatry - December 13, 2023 Category: Psychiatry Source Type: research
Effect of prenatal and early post-natal oxycodone exposure on the reinforcing and antinociceptive effects of oxycodone in adult C57BL/6 J mice
ConclusionPrenatal and early post-natal oxycodone exposure enhanced oxycodone self-administration during adulthood in the C57BL/6 J mice. (Source: Psychopharmacology)
Source: Psychopharmacology - December 13, 2023 Category: Psychiatry Source Type: research
